(Photo by Flickr user Luca Volpi, used under a Creative Commons license)
After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.
Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.
Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.
Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.
Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”
Power Moves: Baltimore Homecoming names co-chairs, executive director
VitusVet moves to Baltimore from Columbia, plans hiring
This Week in Jobs: Win like a champion by scoring your next gig
How SmartLogic accelerated these startups’ product growth trajectories
This Week in Jobs: The first DMV edition
The Baltimore area’s tech sector contributes $21.6B to the local economy
4 strategies Baltimore companies are employing to close the gender gap in tech
This fast-growing SaaS company aims to be a force for change in the energy industry
Sign-up for daily news updates from Technical.ly Baltimore